X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1545) 1545
dicarboxylic acids - pharmacology (939) 939
rats (804) 804
male (696) 696
humans (609) 609
index medicus (495) 495
pharmacology & pharmacy (429) 429
amino acids, dicarboxylic - pharmacology (387) 387
biochemistry & molecular biology (349) 349
mice (329) 329
neurosciences (305) 305
female (285) 285
kinetics (278) 278
dicarboxylic acids (244) 244
in vitro techniques (244) 244
dicarboxylic acids - chemistry (225) 225
dose-response relationship, drug (224) 224
dicarboxylic acids - metabolism (218) 218
cells, cultured (195) 195
pyrrolidines - pharmacology (194) 194
rats, wistar (189) 189
rats, sprague-dawley (176) 176
time factors (170) 170
structure-activity relationship (155) 155
chemistry, medicinal (149) 149
glutamic acid - metabolism (147) 147
glutamate (141) 141
hydrogen-ion concentration (139) 139
neurotransmitter uptake inhibitors - pharmacology (129) 129
expression (128) 128
enzyme inhibitors - pharmacology (121) 121
cell line (115) 115
rats, inbred strains (110) 110
neurons - drug effects (105) 105
excitatory amino acid antagonists - pharmacology (103) 103
dicarboxylic acids - therapeutic use (101) 101
excitatory amino acid agonists - pharmacology (95) 95
cell biology (92) 92
dicarboxylic acids - chemical synthesis (91) 91
oxidation-reduction (91) 91
analysis (90) 90
chemistry (90) 90
hypoxia-inducible factor 1, alpha subunit - metabolism (88) 88
inhibition (88) 88
research article (88) 88
dicarboxylic acids - administration & dosage (87) 87
liver - metabolism (87) 87
biological transport - drug effects (85) 85
hypoxia (85) 85
metabolism (85) 85
physiology (85) 85
pyridines - pharmacology (85) 85
molecular structure (84) 84
chemistry, multidisciplinary (82) 82
binding sites (81) 81
research (81) 81
dicarboxylic-acids (80) 80
activation (77) 77
cycloleucine - analogs & derivatives (77) 77
azelaic acid (76) 76
cycloleucine - pharmacology (76) 76
stereoisomerism (75) 75
adult (74) 74
aspartic acid - pharmacology (74) 74
liver - drug effects (74) 74
cell survival - drug effects (73) 73
biological transport (72) 72
receptors, metabotropic glutamate - agonists (72) 72
guinea pigs (70) 70
brain (69) 69
rabbits (69) 69
amino acids - pharmacology (67) 67
magnetic resonance spectroscopy (67) 67
molecular sequence data (67) 67
cells (66) 66
carrier proteins - metabolism (65) 65
neurons (64) 64
receptors, metabotropic glutamate - antagonists & inhibitors (64) 64
physiological aspects (63) 63
rat (62) 62
calcium - metabolism (61) 61
cell line, tumor (61) 61
chemical phenomena (61) 61
liver - enzymology (60) 60
microdialysis (60) 60
proteins (60) 60
synaptic transmission - drug effects (60) 60
amino acids (59) 59
glycine - pharmacology (59) 59
neurons - metabolism (59) 59
2-aminoadipic acid - pharmacology (58) 58
dicarboxylic acid transporters (58) 58
enzymes (58) 58
gene-expression (58) 58
glycine - analogs & derivatives (58) 58
srs-a - antagonists & inhibitors (58) 58
metabotropic glutamate receptors (57) 57
mice, inbred c57bl (57) 57
oxidative stress (57) 57
release (57) 57
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2295) 2295
German (71) 71
Russian (68) 68
Chinese (17) 17
Japanese (17) 17
Italian (12) 12
French (9) 9
Polish (4) 4
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neuroscience, ISSN 0270-6474, 09/2004, Volume 24, Issue 36, pp. 7821 - 7828
It is widely believed that long-term depression (LTD) and its counterpart, long-term potentiation (LTP), involve mechanisms that are crucial for learning and... 
NR2B | Depotentiation | LTP | NMDARs | LTD | NR2A | HIPPOCAMPAL SYNAPTIC PLASTICITY | RAT | D-ASPARTATE RECEPTORS | PERIRHINAL CORTEX | depotentiation | SUBUNIT COMPOSITION | NEUROSCIENCES | FUNCTIONAL-PROPERTIES | IN-VITRO | AMPA RECEPTORS | GLUTAMATE TRANSPORTERS | EXPRESSION | Receptors, Metabotropic Glutamate - drug effects | Protein Subunits | 2-Amino-5-phosphonovalerate - pharmacology | Neurotransmitter Uptake Inhibitors - pharmacology | Dicarboxylic Acids - pharmacology | Long-Term Synaptic Depression - drug effects | Excitatory Postsynaptic Potentials - drug effects | N-Methylaspartate - pharmacology | Pyrrolidines - pharmacology | Quinoxalines - pharmacology | Neurons - ultrastructure | Long-Term Potentiation - drug effects | Piperidines - pharmacology | Neurons - physiology | Long-Term Potentiation - physiology | Cerebral Cortex - drug effects | Neurons - drug effects | Phenols - pharmacology | Long-Term Synaptic Depression - physiology | Receptors, N-Methyl-D-Aspartate - drug effects | Glutamic Acid - pharmacology | Rats | Excitatory Amino Acid Agonists - pharmacology | Excitatory Amino Acid Antagonists - pharmacology | Receptors, N-Methyl-D-Aspartate - physiology | Animals | Picrotoxin - pharmacology | Cerebral Cortex - physiology | Dizocilpine Maleate - pharmacology | Aspartic Acid - pharmacology | Cellular | Molecular
Journal Article
FASEB Journal, ISSN 0892-6638, 01/2011, Volume 25, Issue 1, pp. 382 - 388
Docosahexaenoic acid (DHA), an important component of marine lipids, exhibits anti-inflammatory activity related to some of its oxygenated metabolites, such as... 
Thromboxane receptor | Docosahexaenoic acid | Docosatrienes | 15-Lipoxygenase | RHEUMATOID-ARTHRITIS | LIPOXYGENASE PRODUCTS | OXIDATIVE STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | 15-lipoxygenase | LIPID MEDIATORS | NEUROPROTECTIN D1 | CELL BIOLOGY | RESPONSES | docosahexaenoic acid | thromboxane receptor | BIOLOGY | CARDIOVASCULAR-DISEASE | docosatrienes | CELL | BRAIN | Dicarboxylic Acids - metabolism | Humans | Thromboxanes - pharmacology | Dicarboxylic Acids - pharmacology | Isomerism | Oxygen - metabolism | Receptors, Thromboxane - antagonists & inhibitors | Platelet Aggregation Inhibitors - pharmacology | Collagen - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - metabolism | Blood Platelets - drug effects | Cyclic AMP - metabolism | Cyclooxygenase Inhibitors - metabolism | Docosahexaenoic Acids - chemistry | Fatty Acids, Unsaturated - pharmacology | Cyclooxygenase Inhibitors - chemistry | Fatty Acids, Unsaturated - metabolism | Cyclooxygenase Inhibitors - pharmacology | Dicarboxylic Acids - chemistry | Docosahexaenoic Acids - pharmacology | Fatty Acids, Unsaturated - chemistry | Blood Platelets - metabolism | Prostaglandin-Endoperoxide Synthases - metabolism | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid - pharmacology | Arachidonic Acid - pharmacology | Platelet Aggregation Inhibitors - chemistry | Receptors, Thromboxane - metabolism | Docosahexaenoic Acids - metabolism
Journal Article
Nature Communications, ISSN 2041-1723, 11/2016, Volume 7, Issue 1, p. 13457
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 05/2014, Volume 78, pp. 86 - 96
Journal Article
Journal Article
Journal of Lipid Research, ISSN 0022-2275, 01/2013, Volume 54, Issue 1, pp. 134 - 151
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other... 
Fatty acid oxidation | LDL-cholesterol | Cardiovascular disease | Cholesterol synthesis | Metabolic syndrome | Fatty acid synthesis | RAT-LIVER | cardiovascular disease | cholesterol synthesis | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACETYL-COA CARBOXYLASE | RECEPTOR-ALPHA | metabolic syndrome | fatty acid synthesis | FATTY-ACID OXIDATION | INSULIN-RESISTANCE | DENSITY-LIPOPROTEIN | fatty acid oxidation | HEXADECANEDIOIC ACID | PEROXISOME PROLIFERATORS | HEPATOCYTE NUCLEAR FACTOR-4-ALPHA | ALPHA,OMEGA-DICARBOXYLIC ACIDS | Carbohydrate Metabolism - drug effects | AMP-Activated Protein Kinases - metabolism | ATP Citrate (pro-S)-Lyase - antagonists & inhibitors | Liver - enzymology | Fatty Acids - therapeutic use | Obesity - drug therapy | Calcium - metabolism | Diet - adverse effects | Humans | Male | Glucose - biosynthesis | Dicarboxylic Acids - pharmacology | Sterols - biosynthesis | Obesity - blood | Dicarboxylic Acids - therapeutic use | Dyslipidemias - blood | Liver - drug effects | Enzyme Inhibitors - chemistry | Female | Obesity - etiology | ATP Citrate (pro-S)-Lyase - metabolism | Molecular Targeted Therapy - methods | Protein-Serine-Threonine Kinases - metabolism | Biomarkers - metabolism | Cricetinae | Dyslipidemias - drug therapy | Fatty Acids - chemistry | Liver - metabolism | Enzyme Inhibitors - pharmacology | Rats | Biomarkers - blood | Enzyme Activation - drug effects | Enzyme Inhibitors - therapeutic use | Hep G2 Cells | Obesity - metabolism | Dicarboxylic Acids - chemistry | Animals | Signal Transduction - drug effects | Lipid Metabolism - drug effects | Dyslipidemias - metabolism | Glucagon - metabolism | Liver - cytology | Mice | Energy Metabolism - drug effects | Fatty Acids - biosynthesis | Fatty Acids - pharmacology
Journal Article
Science, ISSN 0036-8075, 5/2001, Volume 292, Issue 5518, pp. 923 - 926
Analysis of excitatory synaptic transmission in the rat hypothalamic supraoptic nucleus revealed that glutamate clearance and, as a consequence, glutamate... 
Glutamate receptors | Neuroscience | Amino acid transport system XAG | Neurons | Synaptic transmission | Radio transmitters | Reports | OXYTOCIN NEURONS | DIFFERENTIAL EXPRESSION | INHIBITION | TRANSPORTERS | SYNAPSES | MULTIDISCIPLINARY SCIENCES | RAT-BRAIN | INPUTS | HYPOTHALAMIC MAGNOCELLULAR NEURONS | RECEPTORS | PLASTICITY | Lactation | Rats, Wistar | Neurotransmitter Uptake Inhibitors - pharmacology | Amino Acid Transport System X-AG | Aminobutyrates - pharmacology | Receptors, Metabotropic Glutamate - metabolism | Dicarboxylic Acids - pharmacology | Supraoptic Nucleus - physiology | Pyrrolidines - pharmacology | Supraoptic Nucleus - cytology | Excitatory Postsynaptic Potentials | Neurons - physiology | ATP-Binding Cassette Transporters - metabolism | Female | Synaptic Transmission - drug effects | Receptors, AMPA - metabolism | Synapses - physiology | Rats | Excitatory Amino Acid Agonists - pharmacology | Excitatory Amino Acid Antagonists - pharmacology | Astrocytes - physiology | Animals | Glutamic Acid - metabolism | In Vitro Techniques | ATP-Binding Cassette Transporters - antagonists & inhibitors | Receptors, AMPA - antagonists & inhibitors | Neural transmission | Hypothalamic hormones | Research | Glutamate | Nervous system | Neurotransmitters | Cellular biology | Cells | Aminobutyric Acids | Excitatory Amino Acid Agonists | Astrocytes | Neurons and Cognition | Dicarboxylic Acids | Glutamic Aci | Life Sciences | ATP-Binding Cassette Transporters | Excitatory Amino Acid Antagonists
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 08/2013, Volume 38, Issue 9, pp. 1770 - 1779
Kappa-opioid receptors (KORs) are important for motivation and other medial prefrontal cortex (mPFC)-dependent behaviors. Although KORs are present in the... 
aversion | GABA | kappa-opioid receptors | dopamine | prefrontal cortex | glutamate | IN-VIVO MICRODIALYSIS | RAT | PSYCHIATRY | COCAINE | DYNORPHIN | DOPAMINERGIC-NEURONS | NEUROSCIENCES | EXTRACELLULAR GLUTAMATE | NUCLEUS-ACCUMBENS | CORTEX | PHARMACOLOGY & PHARMACY | GLUTAMATE LEVELS | Naltrexone - analogs & derivatives | Analgesics - pharmacology | Narcotic Antagonists - administration & dosage | Synaptic Transmission - physiology | Neurotransmitter Uptake Inhibitors - antagonists & inhibitors | gamma-Aminobutyric Acid - metabolism | Pyrrolidines - antagonists & inhibitors | Neurotransmitter Uptake Inhibitors - pharmacology | Pyrrolidines - administration & dosage | Male | Dicarboxylic Acids - pharmacology | Miniature Postsynaptic Potentials - drug effects | Excitatory Postsynaptic Potentials - drug effects | Pyrrolidines - pharmacology | Excitatory Postsynaptic Potentials - physiology | Naltrexone - pharmacology | Drug Interactions | Prefrontal Cortex - drug effects | Pyramidal Cells - physiology | Synaptic Transmission - drug effects | Dicarboxylic Acids - antagonists & inhibitors | Pyramidal Cells - drug effects | Benzeneacetamides - pharmacology | Naltrexone - administration & dosage | Dopamine - metabolism | Receptors, Opioid, kappa - genetics | Receptors, Opioid, kappa - antagonists & inhibitors | Glutamic Acid - pharmacology | Microinjections | Receptors, Opioid, kappa - agonists | Analgesics - administration & dosage | Rats | Avoidance Learning - physiology | Benzeneacetamides - administration & dosage | Mice, Knockout | Receptors, Opioid, kappa - physiology | Animals | Narcotic Antagonists - pharmacology | Prefrontal Cortex - metabolism | Avoidance Learning - drug effects | Glutamic Acid - metabolism | Mice | Prefrontal Cortex - physiology | Original | opioids
Journal Article
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 04/2017, Volume 37, Issue 4, pp. 647 - 656
OBJECTIVE—Bempedoic acid (ETC-1002, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel low-density lipoprotein cholesterol–lowering compound. In... 
Lipids | Inflammation | Adenosine triphosphate citrate lyase | Atherosclerosis | atherosclerosis | lipids | ACTIVATED PROTEIN-KINASE | CHOLESTEROL | LOWERING THERAPY | LOW-DENSITY-LIPOPROTEIN | ENDOPLASMIC-RETICULUM STRESS | RECEPTOR-DEFICIENT MICE | adenosine triphosphate citrate lyase | inflammation | STATIN THERAPY | INSULIN-RESISTANCE | ETC-1002 | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | HEPATIC STEATOSIS | Dyslipidemias - genetics | ATP Citrate (pro-S)-Lyase - antagonists & inhibitors | Liver - enzymology | Atherosclerosis - genetics | Male | Dicarboxylic Acids - pharmacology | Insulin - blood | Obesity - blood | Obesity - genetics | Inflammation - blood | Dyslipidemias - enzymology | Atherosclerosis - enzymology | Dyslipidemias - blood | Liver - drug effects | Time Factors | Diet, High-Fat | Lipids - blood | Receptors, LDL - deficiency | Dyslipidemias - prevention & control | ATP Citrate (pro-S)-Lyase - metabolism | Disease Models, Animal | Receptors, LDL - genetics | Genetic Predisposition to Disease | Enzyme Inhibitors - pharmacology | Gene Expression Regulation | Inflammation Mediators - blood | Biomarkers - blood | Mice, Knockout | Atherosclerosis - blood | Blood Glucose - drug effects | Phenotype | Animals | Obesity - prevention & control | Inflammation - genetics | Inflammation - prevention & control | Obesity - enzymology | Blood Glucose - metabolism | Inflammation - enzymology | Atherosclerosis - prevention & control | Fatty Acids - pharmacology
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2006, Volume 55, Issue 6, pp. 1048 - 1065
Melasma is an irregular brown or grayish-brown facial hypermelanosis, often affecting women, especially those living in areas of intense UV radiation. The... 
FACIAL HYPERPIGMENTATION | CUTANEOUS PIGMENTED LESIONS | RETINOIC ACID | TOPICAL CORTICOSTEROIDS | DARKER-SKINNED PATIENTS | REFRACTORY MELASMA | AZELAIC ACID | SELECTIVE PHOTOTHERMOLYSIS | SWITCHED RUBY-LASER | GLYCOLIC ACID PEELS | DERMATOLOGY | Clinical Trials as Topic - statistics & numerical data | Humans | Pregnancy Complications | Chemexfoliation | Laser Coagulation | Dicarboxylic Acids - pharmacology | Melanosis - therapy | Adrenal Cortex Hormones - therapeutic use | Hydroquinones - pharmacology | Dicarboxylic Acids - therapeutic use | Flavonoids - therapeutic use | Sunlight - adverse effects | Dicarboxylic Acids - adverse effects | Melanosis - etiology | Adult | Female | Drug Therapy, Combination | Tretinoin - pharmacology | Randomized Controlled Trials as Topic - statistics & numerical data | Double-Blind Method | Gonadal Steroid Hormones - adverse effects | Adrenal Cortex Hormones - pharmacology | Melanosis - drug therapy | Melanosis - prevention & control | Treatment Outcome | Combined Modality Therapy | Dermabrasion | Ultraviolet Rays - adverse effects | Phototherapy | Pregnancy | Adrenal Cortex Hormones - adverse effects | Hydroquinones - adverse effects | Tretinoin - therapeutic use | Skin - radiation effects | Hydroquinones - therapeutic use | Pyrones - therapeutic use | Tretinoin - adverse effects | Medical colleges | Azelaic acid | Radiation | Clinical trials | Dermatologic agents | Melanosis | Health aspects | Tretinoin
Journal Article
Journal of Applied Microbiology, ISSN 1364-5072, 02/2014, Volume 116, Issue 2, pp. 269 - 287
Aims This article describes the qualitative and quantitative analyses of untypical compounds in the cuticular and internal lipids of four dipteran species. For... 
Calliphora vomitoria | Sarcophaga carnaria | Calliphora vicina | Musca domestica | untypical compounds in insects | gas chromatography combined with mass spectrometry | Gas chromatography combined with mass spectrometry | Untypical compounds in insects | AZELAIC ACID | SEBACIC ACID | PHENYLACETIC ACID | COMPONENTS | MICROBIOLOGY | FATTY-ACIDS | THERAPY | METABOLISM | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GROWTH-FACTOR | NEW-ZEALAND HONEYS | EXTRACTIVES | Propionates - pharmacology | Gas Chromatography-Mass Spectrometry | Hydroxybutyrates - chemistry | Humans | Bacteria - drug effects | Male | Antifungal Agents - chemistry | Diptera - chemistry | Dicarboxylic Acids - pharmacology | Phenylacetates - chemistry | Microbial Sensitivity Tests | Lipids - chemistry | Lipids - pharmacology | Aldehydes - pharmacology | Anti-Bacterial Agents - chemistry | Mass Spectrometry | Decanoic Acids - chemistry | Female | Larva - chemistry | alpha-Tocopherol - pharmacology | alpha-Tocopherol - chemistry | Antifungal Agents - pharmacology | Propionates - chemistry | Fungi - drug effects | Decanoic Acids - pharmacology | Dicarboxylic Acids - chemistry | Animals | Anti-Bacterial Agents - pharmacology | Hydroxybutyrates - pharmacology | Phenylacetates - pharmacology | Aldehydes - chemistry | Tocopherols | Bacteria | Lipids | Mass spectrometry | Analysis | Chromatography | Acids | Antimicrobial agents
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 02/2017, Volume 26, Issue 2, pp. 251 - 259
Introduction: Despite the effectiveness of statins in the treatment of lipid disorders, residual risk still exists, and hitherto studies where additional drugs... 
atherosclerosis | ETC-1002 | cardiovascular disease | bempedoic acid | hyperlipidaemia | LOWERING THERAPY | DENSITY-LIPOPROTEIN-CHOLESTEROL | LDL PARTICLE NUMBER | STATIN INTOLERANCE | REDUCING LIPIDS | CARDIOVASCULAR-DISEASE | PHARMACOLOGY & PHARMACY | THERAPEUTIC CHALLENGES | CORONARY-HEART-DISEASE | CITRATE LYASE |